Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 28, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a condition called ANCA associated vasculitis, which affects the kidneys, and aims to understand how changes in kidney metabolism might lead to kidney damage. The researchers will compare different kidney problems to see how they affect kidney function over time. This study is important because it could help doctors find better ways to treat these conditions in the future.
If you are between the ages of 18 and 90 and have been diagnosed with a specific type of kidney problem, you may be eligible to participate. This includes patients with ANCA vasculitis as well as other kidney diseases like minimal change nephropathy or diabetic nephropathy. Participants will be required to provide consent and must have health insurance in France. The trial is currently not recruiting, so it’s not open for enrollment yet, but it’s a great opportunity for those who qualify when it begins. Participants can expect to undergo a kidney biopsy, which is a procedure where a small piece of kidney tissue is taken for testing. It’s important to note that patients who have had a kidney transplant, are on dialysis, or are pregnant cannot participate in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with an indication for initial diagnostic PBR on native kidney
- • 18 ans ≥ Age ≤ 90 ans
- • Affiliation to french health insurance
- • Patient having given consent
- For the ANCA vasculitis group:
- • • Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO)
- For the control groups:
- • • Diagnosis retained after the renal biopsy
- • Interstitial Nephritis
- • Or glomerular nephropathy such as minimal change nephropathy
- • Or Segmental hyalinosis in itscollapsing form
- • Or Extramembranous Glomerulopathy,
- • Or glomerulopathy with mesangial IgA deposits
- • Or diabetic nephropathy.
- Exclusion Criteria:
- • Kidney transplant patient
- • Patient on dialysis (hemodialysis or peritoneal dialysis)
- • Patient under legal protection, guardianship or curatorship
- • Pregnancy or breastfeeding
- • Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Marine LIVROZET
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported